The safety of using anti-VEGF: Is there strength in numbers? Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128(10):1273–1279

David Wong,Antonia M Joussen

doi:10.1007/s00417-010-1603-7

The safety of using anti-VEGF: Is there strength in numbers? Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128(10):1273–1279

David Wong, Antonia M Joussen

Open Access

https://doi.org/10.1007/s00417-010-1603-7

Copy DOI

Journal: Albrecht von Graefes Archiv f�r Klinische und Experimentelle Ophthalmologie	Publication Date: Jan 6, 2011
Citations: 18	License type: cc-by-nc

Affiliation: Hong Kong Eye Hospital, University of Hong Kong, Charité - Universitätsmedizin Berlin

#Hazard Of Myocardial Infarction #Bevacizumab Group + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

The safety of using anti-VEGF: Is there strength in numbers? Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128(10):1273–1279

Full Text